Graybug Vision, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Graybug Vision, Inc.
Private Company Edition: Deerfield is funding a new life science campus. Also, BioFractura gets up to $67.4m in BARDA contract in recent grant and government deal surge, Mission Bay raises a $60m fund and Amphivena closes a $62m VC round.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in July and August.
Private Company Edition: The start-up intends to take multiple drug candidates into the clinic by 2021. Also, Graybug Vision raises an $80m series B and Finch closes a $53m series C.
Allergan has been developing abicipar to provide less-frequent dosing in neovascular AMD, but despite success in reducing intraocular inflammation with a new formulation, the injectable still doesn’t match the safety of entrenched competitors.
- Drug Delivery
- Controlled Release
- Site Specific
- Nanotechnology, Chips, etc.
Drug Discovery Tools
- Other Names / Subsidiaries
- GrayBug, Inc.
- GRAYBUG LLC